Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2640MR)

This product GTTS-WQ2640MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001290023.2; NM_001258214.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3594; 3595
UniProt ID P42701; Q99665
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2640MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2050MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ3104MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ7205MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ7975MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ10378MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ3885MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ14388MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ3472MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BA1126
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW